Search
Now showing items 1-5 of 5
Pharmacotherapy in COVID-19 patients: a review of ACE2-raising drugs and their clinical safety
(
Taylor and Francis Ltd
, 2020 , Article Review)
The COVID-19 pandemic is caused by the severe acute-respiratory-syndrome-coronavirus-2 that uses ACE2 as its receptor. Drugs that raise serum/tissue ACE2 levels include ACE inhibitors (ACEIs) and angiotensin-II receptor ...
The Role of Epidermal Growth Factor Receptor Family of Receptor Tyrosine Kinases in Mediating Diabetes-Induced Cardiovascular Complications
(
Frontiers Media S.A.
, 2021 , Article)
Diabetes mellitus is a major debilitating disease whose global incidence is progressively increasing with currently over 463 million adult sufferers and this figure will likely reach over 700 million by the year 2045. It ...
In honour of Professor Jackie Ying, recipient of the Journal of Drug Targeting's Lifetime Achievement Award�for 2020
(
Taylor and Francis Ltd
, 2020 , Article)
[No abstract available]
In honour of Professor Patrick Couvreur, recipient of the Journal Of Drug Targeting?s Lifetime Achievement Award For 2019
(
Taylor and Francis Ltd
, 2019 , Article)
[No abstract available]
Is there truly an increase in risk of cardiovascular and hematological adverse events with vascular endothelial growth factor receptor tyrosine kinase inhibitors?
(
Taylor and Francis Ltd
, 2020 , Article)
Objectives: Recent studies have shown an increase risk of cardiovascular and hematological adverse events associated with vascular endothelial growth factor tyrosine kinase inhibitors (VEGF-TKIs). The authors hypothesize ...